IM Therapeutics locks in $10 mln Series A
Woburn, Massachusetts-based mmunoIMolecular Therapeutics, a developer of personalized therapies for autoimmune disease, has raised $10 million in Series A financing. JDRF T1D Fund and Morningside Ventures led the round with participation from the Colorado University Healthcare Innovation Fund.
10 October 2019•1 min read
